Media Room Menu
Month Year
Su | Mo | Tu | We | Th | Fr | Sa |
---|---|---|---|---|---|---|
Month Year
Su | Mo | Tu | We | Th | Fr | Sa |
---|---|---|---|---|---|---|
-
Apr 26, 2019* Praluent is the first PCSK9 inhibitor that has shown a meaningful reduction in death from any cause
-
Apr 24, 2019- Top-line Data Anticipated in the Fourth Quarter of 2019 -
-
Apr 10, 2019* Sanofi continues its commitment to helping reduce cost burden for people living with diabetes with first-ever insulin savings program
-
Apr 9, 2019Pivotal Study to Evaluate Potential of Anti-CD3 Monoclonal Antibody to Intercept Type 1 Diabetes
-
Apr 2, 2019Strengthens Leadership Team with Appointment of Douglas Jacobstein, M.D. as V.P. of Clinical Development and Alex Rabiee as V.P. of Business Development
-
Mar 28, 2019Dr. Bluestone is a World-renowned Expert and Academic Leader in Immune Tolerance Research
-
Mar 19, 2019Plan to Initiate PROTECT Study for PRV-031 (teplizumab) in T1D Patients in Q2
-
Mar 11, 2019* Only therapy that targets the IL-4/IL-13 pathway, a key driver of the allergic or type 2 inflammation that underlies atopic dermatitis
-
Feb 27, 2019* Soliqua 100/33 now approved as an add-on to diet and exercise for adults with type 2 diabetes
-
Feb 25, 2019Praluent® (alirocumab) continues to be available in the U.S.
-
Feb 11, 2019* This is the latest step by the companies to help make Praluent more accessible and affordable for appropriate patients
-
Feb 6, 2019- First medicine approved in the U.S. specifically for the treatment of aTTP, a rare blood-clotting disorder
-
Jan 28, 2019Provention is currently developing PRV-101 as a polyvalent vaccine for acute coxsackie virus infection and to potentially prevent the onset of T1D
-
Jan 23, 2019- The 0.5 mL dose is now approved for use in children 6 months through 35 months of age
-
Jan 14, 2019* First and only vaccine approved in the U.S. for repeat vaccination 8 years or more after the first vaccination to help protect against tetanus, diphtheria and pertussis, offering flexibility for health care providers to help manage their immunization schedules(2)
-
Jan 9, 2019-HERCULES Phase 3 trial met its primary endpoint, demonstrating that treatment with Cablivi resulted in a significantly faster time to platelet count response in patients with acquired thrombotic thrombocytopenic purpura (aTTP) when administered in conjunction with plasma exchange and immunosuppression
-
Jan 3, 2019Provention is currently developing PRV-101 as a vaccine for acute coxsackie infection and to potentially prevent the onset of T1D